Krishna Institute of Medical Sciences Ltd (KIMS) Q1 FY27 Earnings Call: Guides Kondapur at Rs. 1,200 Cr Revenue, Debt Reduced to Rs. 2,400 Cr

Krishna Institute of Medical Sciences Ltd held its Q1 FY27 earnings call on August 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Operating Metrics

• Consolidated revenue from operations of Rs.1,180 crore in Q1 FY 2026-2027, reflecting strong 25.3% YoY growth; total revenue including other income reached Rs.1,196 crore (+36.1% YoY).
• Consolidated EBITDA pre-Ind AS at Rs.222 crore (+14.6% YoY); total EBITDA at Rs.240 crore (+20.1% YoY). PAT fell to Rs.37 crore from Rs.85 crore in Q1 FY 2025-2026, impacted by pre-operative costs and interest on debt before QIP proceeds were deployed.
• IP volumes grew 26.6% YoY to 72,493 and OP volumes grew 28.5% YoY to 6,58,617 in Q1 FY 2026-2027, reflecting strong patient demand across clusters.
• Average revenue per operating bed grew 9.7% YoY and average revenue per patient (ARPP) grew 6.8% YoY in Q1 FY 2026-2027, supported by case mix and quaternary care focus.
• Cash and equivalents stood at Rs.505 crore as of 30 June 2026, providing liquidity headroom post-QIP.

QIP, Debt Reduction and Cash Flow Outlook

• Rs.1,500 crore QIP (oversubscribed) and a Rs.600 crore preferential allotment to promoters closed in the quarter; ~Rs.1,100 crore of QIP proceeds used to repay secured loans on June 27-28, 2026, with interest cost relief visible from Q2 FY 2026-2027 onwards.
• Gross debt reduced from Rs.3,250 crore (31 March 2026) to Rs.2,570 crore (30 June 2026), and further to ~Rs.2,400 crore after additional repayments in early July 2026; management targets total debt reduction of Rs.1,300 crore.
• Maintenance capex guided at Rs.100 crore per year for the next 3-4 years (FY 2027-2028 to FY 2030-2031), with management expecting operating cash flow of Rs.2,500+ crore over the same period, leaving ~Rs.2,000 crore for growth investments.
• Internal accruals likely deployed for greenfield/brownfield growth rather than further debt reduction, with a target debt-to-equity ratio of 2.5:1; minority interest guided at 10-15% of PAT over the longer term (Q1 FY 2026-2027: 10.5%).
• Government receivables showing a positive trend with more timely payments, partially mitigating a prior working capital risk per CFO commentary.

Kondapur, Bangalore, Maharashtra and Kerala Progress

• Kondapur new unit admitted its first patient on 20 June 2026 and delivered Rs.45 crore revenue in July 2026 (first full month, Q2 FY 2026-2027), up 30-40% from the June run-rate; management guided full potential of ~Rs.100 crore per month (~Rs.1,200 crore annualized) over the next 4-5 years as oncology and transplant programs launch.
• Mahadevapura (Bangalore) achieved EBITDA breakeven in <7 months and recorded Rs.20 crore revenue in July 2026; Electronic City expected to reach EBITDA breakeven by end of FY 2026-2027, with management targeting the Bangalore cluster at zero EBITDA loss for the full year.
• Thane (Maharashtra) had a weak Q1 FY 2026-2027 due to seasonality and empanelment delays, but July revenue improved to Rs.21 crore with 10% EBITDA margin; Nagpur delivered a record Rs.50 crore revenue in July 2026, though Maharashtra ramp remains slower than South India due to part-time doctor conversion timelines.
• Kerala cluster (investment Rs.110 crore) reported revenue of ~Rs.77 crore in Q1 FY 2026-2027 with single-digit EBITDA margins; management expects mid-teens margins in FY 2027-2028 and 20-22% stability over 2-3 years, adjusted from 22-23% guidance after accounting for 4-5% rental costs on most assets.
• Bangalore and Maharashtra clusters each guided for 15-20% YoY growth in FY 2026-2027, with the Bangalore cluster ARPOB stabilizing at Rs.80,000-85,000 once corporate and government empanelments are completed.

EBITDA Margin Trajectory by Cluster and Occupancy Levers

• Telangana segment delivered 31% EBITDA margin in FY 2025-2026 (mature hospitals: Secunderabad 34-35%, Kondapur pre-expansion 34-35%, Sunshine 38-39% in Q4 FY 2025-2026); management maintains a 30-35% EBITDA margin outlook but notes new bed capacity will delay return to 30%+.
• Excluding 200 beds under renovation in Secunderabad and 500 new beds at Kondapur, the existing hospital cluster operated at ~61% occupancy in Q1 FY 2026-2027; management guided that without further capacity additions, occupancy could reach 65-70% by FY 2027-2028, enabling EBITDA margins of 28-30%.
• Old Kondapur hospital (33% EBITDA margin in FY 2025-2026) remains operational for ~6 more months (within FY 2026-2027), incurring Rs.90 lakhs + GST per month rent plus operating costs; a decision on its future is expected around Q4 FY 2026-2027.
• New Kondapur modeled at 30-32% EBITDA margin at the Rs.1,200 crore revenue potential, with 35-40% margins requiring more time to mature; management expects margins to stay suppressed for ~2 years as clinical programs ramp.
• Long-term group margin target ramps from mid-single digit for FY 2026-2027 to 20-22% over the next 3-4 years; management will share a separate EBITDA margin trajectory note for H2 FY 2026-2027 and FY 2027-2028.
• ARPOB growth guided at 4-5% per annum, below the historical 15-16% trend and below inflationary expectations of 6-7%, reflecting the impact of new units and empanelment mix.

Bed Expansion, Greenfield Pipeline and O&M Agreements

• Operational beds in Bangalore increased from 280 to 340 in Q1 FY 2026-2027, with 40 beds added at Mahadevapura (170 to 210); census bed occupancy at Mahadevapura is ~40%, and further census beds will be added only when occupancy reaches 55-60%.
• Telangana operational beds rose ~450 quarter-on-quarter entirely from Kondapur beds commissioned in the last 10 days of Q1 FY 2026-2027; occupied beds were flattish QoQ as new beds were only operational for a short period.
• Greenfield opportunities in core geographies (Telangana, Andhra, Maharashtra, Karnataka, Kerala) will be pursued in FY 2027-2028; no new geographies are being considered. Acquisitions are pursued only in existing home markets targeting 300-350 bed assets scalable by ~100 beds.
• KIMS signed O&M agreements with Golden Land Solutions and Talbottum Healthcare for two hospitals: one near Kondapur (revenue potential Rs.19-20 crore per month) and one in Kakinada, Andhra Pradesh (current revenue Rs.7-8 crore, scalable to Rs.15-20 crore). KIMS receives a percentage of revenue with no losses hitting its P&L.
• Capex in Q1 FY 2026-2027 was Rs.60-75 crore; management guided Rs.100-125 crore for the remaining nine months of FY 2026-2027, primarily for the Srinagar flagship unit, Rajahmundry (Rs.60-75 crore), and minor work at Kundapur.
• Brownfield expansion opportunities identified in Kerala, Telangana, and Maharashtra; timing subject to opportunity. Management declined to quantify incremental bed additions for FY 2028-2029 beyond already announced projects.

Telangana, Andhra Pradesh, Karnataka, Kerala and Maharashtra Trends

• Hyderabad Telangana cluster is performing as planned with strong YoY revenue and EBITDA growth in Q1 FY 2026-2027 (ex-Kondapur); management targets 70% occupancy for the cluster over the next 3-4 years, with current reported ~50-52% depressed by 250 demolished beds still listed as capacity.
• Andhra Pradesh cluster growth moderated in Q1 FY 2026-2027 vs Q4 FY 2025-2026, but management attributed this to seasonal and case mix changes, not structural issues; cancer specialties have been added in most AP hospitals over the last 2-3 months, with Q2 expectations of improvement.
• Karnataka cluster delivered high ARPPs from complex cases, outperforming initial expectations; doctor hiring for FY 2026-2027 is largely complete, though additions will continue as hospitals mature.
• Kerala cluster reported ~Rs.77 crore revenue in Q1 FY 2026-2027 at single-digit EBITDA margins; the newly opened Palakkad unit is ramping up, and Thrissur is scheduled to launch in 3-4 months.
• Maharashtra (Nagpur) cluster is ramping gradually as patient and doctor mindset aligns with KIMS culture; Nagpur delivered a record Rs.50 crore revenue in July 2026, and management sees strong long-term potential but expects slow growth until the market matures.
• Common empanelment initiative involving GIC — management noted "some clarity is emerging" and that "GIC and insurance companies are adjusting," with the impact expected to "settle down over the next few months." The previous fiscal year (FY 2025-2026) was challenging due to the timing of GIC's common council announcement.
• Management expects YoY growth in top line and bottom line in FY 2026-2027, consistent with historical performance, and stated the company is in good shape, performing better than expected.